HER2 expression and its clinicopathological features in resectable gastric cancer
- 14 March 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 16 (1), 84-93
- https://doi.org/10.1007/s10120-012-0150-9
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Low frequency of HER2 amplification and overexpression in early onset gastric cancerCellular Oncology, 2011
- HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)Histopathology, 2011
- Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinomaWorld Journal of Gastroenterology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- A study of HER2 gene amplification and protein expression in gastric cancerJournal of Clinical Pathology, 2010
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingVirchows Archiv, 2010
- Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significanceZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patientsBritish Journal of Cancer, 2009
- HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric CancerDigestive Diseases and Sciences, 2006
- p53 point mutations in primary human gastric carcinomasZeitschrift für Krebsforschung und Klinische Onkologie, 1992